Olema Oncology Partners with Bayer to Test OP-3136 in Prostate Cancer Trial — Olema Pharmaceuticals, Inc.

Event summary

Olema Oncology and Bayer AG have entered a clinical trial collaboration to evaluate OP-3136 in combination with NUBEQA® (darolutamide) in metastatic castration-resistant prostate cancer (mCRPC).
The Phase 1b/2 study will involve approximately 36 patients and is expected to initiate in the second half of 2026.
Bayer will supply darolutamide for the study, while Olema will lead the clinical trial and maintain full global commercial rights to OP-3136.
Olema will present initial clinical data from the Phase 1 study of OP-3136 at the ASCO Annual Meeting on May 30, 2026.

The big picture

This collaboration marks Olema's first clinical partnership for OP-3136, expanding its focus beyond breast cancer into metastatic prostate cancer. The deal underscores the growing interest in combination therapies for aggressive cancers, particularly as epigenetic targets like KAT6 gain traction. With Bayer's established presence in oncology, the partnership could accelerate OP-3136's development timeline and broaden its commercial potential.

What we're watching

Clinical Trial Progress: The pace at which the Phase 1b/2 study initiates and enrolls patients will indicate Olema's operational efficiency and the potential for timely data readouts.
Combination Strategy: Whether the combination of OP-3136 and darolutamide demonstrates synergistic anti-tumor activity could validate Olema's approach to targeting metastatic prostate cancer.
Regulatory Milestones: The outcome of the ASCO presentation and subsequent regulatory interactions will shape the path forward for OP-3136 in both prostate cancer and other solid tumors.